The authors of the publication below utilized the active human PAI-1 functional assay ELISA kit from Molecular Innovations.
“Among a cohort of ambulatory patients at intermediate to high risk of VTE, these exploratory findings suggest that baseline activation of coagulation and fibrinolysis pathways vary significantly by tumor type and disease stage.”
“Active PAI-1 in PFP (i.e., the fraction that is unbound to tPA or u-PA, and therefore retains full inhibitory capacity) was measured by ELISA (Molecular Innovations, Novi, MI, USA, cat. no. HPAIKT), according to the manufacturer’s specifications.”
“Patients with pancreatic cancer and metastasis to 2 or more sites had elevated levels of aPAI-1.”
[From Abstract:] Plasma kallikrein (pKal) is a serine protease responsible for cleaving high-molecular-weight kininogen to produce the pro-inflammatory peptide, bradykinin. Unregulated pKal activity can lead to hereditary angioedema (HAE) following excess bradykinin release. HAE attacks can lead to a compromised airway that can be life threatening. As there are limited agents for prophylaxis of HAE attacks, there is a high unmet need for a therapeutic agent for regulating pKal with a high degree of specificity… [continue reading]
Cited Products: Human Kallikrein, Equine Kallikrein, Human Factor XIIA, Human TPA
Full Citation: Partridge J, Choy R, Silva-Garcia A, et al. Structures of full-length plasma kallikrein bound to highly specific inhibitors describe a new mode of targeted inhibition. Journal of Structural Biology. In Press, Accepted Manuscript. Available Online 12 March 2019.